Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Calcium channel blockers in heart failure]

T Hole1, K Dickstein, T Gundersen

  • 1Medisinsk avdeling, Sentralsjukehuset i Møre og Romsdal, Alesund.

Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke
|June 20, 1997
PubMed
Summary

Calcium channel blockers are not recommended for patients with heart failure due to impaired calcium delivery and sympathetic reflexes. Amlodipine or felodipine may be considered for angina when other treatments fail.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tumour biomarkers: association with heart failure outcomes.

Journal of internal medicine·2020
Same author

EUROPEAN CARDIAC RESYNCHRONIZATION THERAPY SURVEY II: COMPARISON OF RESULTS IN GEORGIA WITH OTHER COUNTRIES.

Georgian medical news·2019
Same author

Novel endotypes in heart failure: effects on guideline-directed medical therapy.

European heart journal·2018
Same author

Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study.

European heart journal·2017
Same author

Repetitive use of levosimendan for treatment of chronic advanced heart failure: clinical evidence, practical considerations, and perspectives: an expert panel consensus.

International journal of cardiology·2014
Same author

Clinical predictors of sleep apnoea in heart failure outpatients.

International journal of clinical practice·2014

Area of Science:

  • Cardiology
  • Pharmacology

Context:

  • Heart failure patients exhibit impaired calcium handling and attenuated sympathetic reflexes.
  • Systolic left ventricular dysfunction complicates the use of calcium channel blockers.

Purpose:

  • To evaluate the role and safety of calcium channel blockers in patients with heart failure and coronary artery disease.
  • To identify potential therapeutic alternatives for angina in specific cardiac conditions.

Summary:

  • Calcium channel blockers (CCBs) are generally contraindicated in heart failure with systolic left ventricular dysfunction.
  • These agents can exacerbate the condition due to underlying myocardial calcium delivery defects and altered sympathetic responses.
  • For patients with coronary artery disease experiencing angina unresponsive to beta-blockers or nitrates, specific CCBs like amlodipine or felodipine may be cautiously considered.

Related Experiment Videos

Impact:

  • This guidance aims to prevent adverse events and optimize treatment strategies for patients with complex cardiovascular conditions.
  • Highlights the need for individualized treatment approaches in managing heart failure and angina concurrently.